TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03793842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP titration by EIT
Description: PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP titration by EIT
Description: PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
Study: NCT03409289

Intervention type: DEVICE
Intervention: RUSH Exam
Description: Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
Study: NCT01011751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Description: Cyproterone acetate tablet-in-capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Description: Medroxyprogesterone acetate tablet-in-capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
Study: NCT01010529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupational therapy
Description: Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
Study: NCT02008110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Up titration of loop diuretics according to plasma levels of CA125 in the active arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Consider statins in all patients in the active arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Consider omega-3 polyunsaturated fatty acids in the active arm
Study: NCT00244114

Intervention type: DRUG
Intervention: blood draw
Description: Single blood sample collected to perform histamine release assay.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Single blood sample collected to perform histamine release assay.
Study: NCT04166994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and diet
Description: IMPACT Intervention
Study: NCT04350437

Intervention type: DRUG
Group type: OTHER
Intervention: induction of labor
Description: Giving drugs to facilitate uterine contractions and fasten the process of delivery
Study: NCT02955095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quit Smoking Phone Application
Description: The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
Study: NCT01268618

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:~1. Lactobacillus acidophilus NAS, 30 billion CFU~2. Bifidobacterium bifidum Malyoth, 120 billion CFU~3. Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules, 3x/day placebo capsules
Study: NCT05126069

Intervention type: DEVICE
Intervention: Ab interno gelatin microstent
Description: Ab interno gelatin microstent

Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: Trabeculectomy
Study: NCT01859169

Intervention type: PROCEDURE
Intervention: Photodynamic therapy
Description: Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
Study: NCT01984632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic myomectomy
Description: The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port laparoscopic myomectomy
Description: The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
Study: NCT01591057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 portions of fruit and vegetables per day
Description: Consume 2 portions of fruit and vegetables per day
Study: NCT02008110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Frequency of monitoring according plasma evolution of CA125 in the active arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment strategy
Description: All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
Study: NCT02752945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-day CBT workshop
Description: One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
Study: NCT04166994

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention: Usual Care
Description: No exercise or diet specialization.
Study: NCT06333054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrethrum Extract
Description: Treatment with Goldgeist® Forte

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silcap Shampoo
Description: Treatment with Silcap Shampoo
Study: NCT04221997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sertraline
Description: Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
Study: NCT01591057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 portions of fruit and vegetables per day
Description: Consume 5 portions of fruit and vegetables per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 8 portions of fruit and vegetables per day
Description: Consume 8 portions of fruit and vegetables per day
Study: NCT02752945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care afforded by local CAMHS services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care afforded by local CAMHS services
Study: NCT03822052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated ringers
Description: IV fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated ringers
Description: IV fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated ringers
Description: IV fluid
Study: NCT00858455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 and MaaloxAdvanced Maximum Strength
Description: A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 and Maalox Advanced Maximum Strength
Description: A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 and One A Day
Description: A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: A single dose of GSK1349572
Study: NCT01692379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solitaire FR device
Description: Mechanical embolectomy in anterior large vessel occlusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Standard of care in acute ischemic stroke including intravenous rTPA
Study: NCT03318497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
Description: Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01927315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg
Description: Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo tablets once daily
Study: NCT04059029

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
Study: NCT03813082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged wakefulness
Description: 40 hours of prolonged wakefulness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged wakefulness
Description: 40 hours of prolonged wakefulness
Study: NCT02973503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir Fixed Dose Combination
Description: Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
Study: NCT00983060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIM811
Description: BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
Study: NCT03822052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated ringers
Description: IV fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose lactated ringers
Description: IV fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose lactated ringers
Description: IV fluid
Study: NCT00983060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID + SOC
Description: Placebo BID + SOC (PEG IFN and RBV)
Study: NCT01452893

Intervention type: PROCEDURE
Intervention: Spiroergometry
Description: At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP).

Intervention type: PROCEDURE
Intervention: Spiroergometry
Description: At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP).

Intervention type: PROCEDURE
Intervention: Spiroergometry
Description: At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP).

Intervention type: PROCEDURE
Intervention: Spiroergometry
Description: At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP).
Study: NCT00638716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC
Description: 1.5 or 2.0 mg CJC-1134-PC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC
Description: 1.5 or 2.0 mg CJC-1134-PC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04416867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint and home exercise
Description: Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESWT
Description: RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
Study: NCT03822052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose lactated ringers
Description: IV fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose lactated ringers
Description: IV fluid
Study: NCT04098081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Therapeutic
Study: NCT04215055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibraject
Description: VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
Study: NCT03461003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICHE method
Description: Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Calcium-channel blocker; antihypertensive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Thiazide diuretic; antihypertensive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Angiotensin II receptor blocker (ARB); antihypertensive
Study: NCT03583918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HighThroughput Micro Coring Device
Description: Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
Study: NCT01421433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tandrilax
Description: Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolamin Flex
Description: Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
Study: NCT02696655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Description: Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
Study: NCT03460977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous
Study: NCT02737670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: 25 mg morning and evening for 40 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet morning and evening for 40 days
Study: NCT03460977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mervometostat (PF-06821497)
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral continuous
Study: NCT04082546

Intervention type: PROCEDURE
Intervention: Surgical unroofing of muscle-briged coronary artery
Description: Medical therapy with beta-blockers or calcium-channels blockers

Intervention type: PROCEDURE
Intervention: Surgical unroofing of muscle-briged coronary artery
Description: Medical therapy with beta-blockers or calcium-channels blockers
Study: NCT04162769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod 1 mg
Description: Etrasimod 1 mg tablet taken by mouth, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Description: Etrasimod 2 mg tablet taken by mouth, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Description: Etrasimod 2 mg tablet taken by mouth, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etrasimod matching placebo
Description: Etrasimod matching placebo tablet by mouth, once daily.
Study: NCT02635854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Septic choc group
Description: Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Orthopedic surgery group
Description: Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
Study: NCT02193984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Study: NCT03214718

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day
Description: For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry .
Study: NCT03734614

Intervention type: DRUG
Intervention: Low dose of aspirin
Description: Low dose of aspirin, 100 mg daily for longer than one year